Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer

BACKGROUND: In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the tumor biopsy spatiotemporal heterogeneity. However, the prognostic significance of PD-L1-positive [PD-L1((+))] CTCs remains controversial. METHODS: We prospectively evaluated the correlation with clinicopathological variables and prognostic value of PD-L1((+)) CTCs, detected with the FDA-cleared CellSearch (R) system, in 54 patients with advanced NSCLC. RESULTS: We detected CTCs and PD-L1((+)) CTCs in 43.4% and 9.4% of patients with NSCLC. PD-1,1 expression concordance between tumor tissue and CTCs was low (54%). The presence of PD-L1((+)) CTC correlated with the absence of gene alterations in tumor tissue and with poor prognosis-related biological variables (anemia, hyponatremia, increased lactate dehydrogenase). In univariate analysis, absence of gene alterations, number of metastatic sites, prior systemic therapies, and presence of CTCs and PD-L1((+)) CTCs were associated with worse overall survival, whereas PDL1 expression in tumor tissue was not. In multivariate analysis, squamous cell carcinoma histology, number of prior systemic treatments, and the presence of CTC were significantly associated with overall survival. Survival was worse in patients with PD-L1((+)) CTCs than in patients with PD-Ll-negative CTC or without any CTC. CONCLUSIONS: Our study suggests that the presence of PD-L1((+)) CTCs is associated with poor prognosis in patients with advanced NSCLC. Studies with larger samples are needed to confirm our results and to determine how PD-L1((+)) CTC detection could help to predict the response or resistance to anti-PD-1/PD-L1 therapies.

Automated summary

The presence of PD-L1(+) CTCs is associated with poor prognosis in patients with advanced NSCLC, showing low concordance with PD-L1 expression in tumor tissue, and further studies with larger samples are needed for confirmation.